These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30277096)

  • 1. BACE inhibitors in clinical development for the treatment of Alzheimer's disease.
    Panza F; Lozupone M; Solfrizzi V; Sardone R; Piccininni C; Dibello V; Stallone R; Giannelli G; Bellomo A; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
    Expert Rev Neurother; 2018 Nov; 18(11):847-857. PubMed ID: 30277096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
    Imbimbo BP; Watling M
    Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
    [No Abstract]   [Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Secretase Targeting for Alzheimer's Disease Therapy.
    Miranda A; Montiel E; Ulrich H; Paz C
    J Alzheimers Dis; 2021; 81(1):1-17. PubMed ID: 33749645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.
    Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease.
    Evin G; Barakat A
    Degener Neurol Neuromuscul Dis; 2014; 4():1-19. PubMed ID: 32669897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of beta-secretase inhibitors for Alzheimer's disease.
    Albert JS
    Prog Med Chem; 2009; 48():133-61. PubMed ID: 21544959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease.
    Lee J; Samson AAS; Song JM
    Anal Chim Acta; 2018 Aug; 1022():89-95. PubMed ID: 29729742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
    Evin G
    BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
    Nawrot B
    Acta Biochim Pol; 2004; 51(2):431-44. PubMed ID: 15218540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
    Hook VY; Toneff T; Aaron W; Yasothornsrikul S; Bundey R; Reisine T
    J Neurochem; 2002 Apr; 81(2):237-56. PubMed ID: 12064471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease.
    Fukumoto H; Cheung BS; Hyman BT; Irizarry MC
    Arch Neurol; 2002 Sep; 59(9):1381-9. PubMed ID: 12223024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug candidates in clinical trials for Alzheimer's disease.
    Hung SY; Fu WM
    J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
    Hook VY; Reisine TD
    J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.